Abstract: This invention provides novel aryl piperazine derivatives represented by Formula (I) having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D₅, 5HT₁₅, and 5-HT₂A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.
ARYL PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS

TECHNICAL FIELD

This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D₃, 5HT₁A and 5-HT₂A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.

BACKGROUND ART

Dopamine is involved in several important functions, excitatory and inhibitory, via dopaminergic receptors in the central and peripheral nervous system. Dopamine receptors were originally classified into two main groups: D₁ and D₂. The five currently cloned dopamine receptors fall into these classes. Thus, the D₁-like receptors include D₁ and D₅, while the D₂-like receptors include D₂, D₃ and D₄.

The dopamine receptors, and in particular the D₂-like receptors, are recognised as potential therapeutic targets for various neurological and psychiatric disorders, in particular psychotic disorders, incl. schizophrenia. Other therapeutic indications associated with the dopamine receptors include depression, Parkinson's disease, Huntington's disease, movement disorders such as dystonia, anxiety, restlessness, obsessive-compulsive disorders, mania, geriatric disorders, dementia, sexual dysfunction, musculo-skeletal pain symptoms, e.g. pain associated with fibromyalgia, substance abuse (cocaine abuse and addiction), abuse liability and withdrawal symptoms in drug addicts, and sleep disorders.

Still other therapeutic indications include eating disorders such as overeating, compulsive overeating, inability to regulate eating, bulimia and Binge-eating disorder.

Also the compounds of the invention may be useful for the treatment of abuse liability and withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, cannabis, benzodiazepines, benzodiazepine-like drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.

Finally receptor selective ligands find use as diagnostic tools in diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging).
WO 2006/072608 describes aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors. However, the aryl piperazine derivatives of the present invention have not been reported.

SUMMARY OF THE INVENTION

According to the present invention it has now been found that a particular group of aryl piperazine derivatives show superior activity as modulators of dopamine and serotonin receptors, preferably the D₃, 5HT₁ₐ and 5-HT₂ₐ receptor subtypes, has no significant activity on hERG, and has a good bioavailability when administered p.o.

Therefore, in its first aspect, the invention provides novel aryl piperazine derivatives represented by Formula I

![Formula I](image)

an enantiomer thereof or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein,

R¹, R² and R³, independently of each other, represent hydrogen, methyl, hydroxy, methoxy, halo, trifluoromethyl, cyano or carboxy.

In another aspect the invention relates to the use of the aryl piperazine derivative of the invention, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition.

Viewed from yet another aspect the invention relates to the use of the aryl piperazine derivative of the invention, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, for use as a medicament, or for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the dopamine and serotonin receptors.

In a final aspect the invention provides a method of diagnosis, treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the dopamine and serotonin receptors, in particular the D₃, D₂-like and 5-HT₂ receptor subtypes, preferably the dopamine D₃ receptor subtype and/or the D₃/5-HT₁ₐ or D₃/5-HT₂ₐ receptor subtypes, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective
amount of the aryl piperazine derivative of the invention, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.

DETAILED DISCLOSURE OF THE INVENTION

According to the present invention it has now been found that a particular group of aryl piperazine derivatives show a superior biological profile as modulators of dopamine and serotonin receptors.

Therefore, in its first aspect, the invention provides novel aryl piperazine derivatives represented by Formula I

\[
\text{Formula I}
\]

an enantiomer thereof or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein, \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, methyl, hydroxy, methoxy, halo, thfluoromethyl, cyano or carboxy.

In a preferred embodiment the aryl piperazine derivative of the invention is a compound of Formula I, wherein \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, methyl, methoxy, halo, trifluoromethyl, cyano or carboxy.

In another preferred embodiment the aryl piperazine derivative of the invention is a compound of Formula I, wherein \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, methyl, hydroxy, methoxy, halo, or trifluoromethyl.

In a more preferred embodiment \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, methyl, methoxy, halo or trifluoromethyl.

In an even more preferred embodiment \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, hydroxy or halo.

In a still more preferred embodiment \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen or halo.

In a third preferred embodiment the aryl piperazine derivative of the invention is a compound of Formula I, wherein \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, halo, hydroxy or trifluoromethyl.

In a more preferred embodiment \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, halo or trifluoromethyl.
In an even more preferred embodiment \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen or halo.

In a fourth preferred embodiment the aryl piperazine derivative of the invention is a compound of Formula 1, wherein \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen, fluoro, chloro, bromo or trifluoromethyl.

In a more preferred embodiment \( R_1, R_2 \) and \( R_3 \), independently of each other, represent hydrogen or fluoro.

In a fifth preferred embodiment the aryl piperazine derivative of the invention is a compound of Formula 1, wherein one of \( R_1, R_2 \) and \( R_3 \), represents hydrogen or hydroxy; and the two others of \( R_1, R_2 \) and \( R_3 \), independently of each other, represent methyl, methoxy, halo, trifluoromethyl, cyano or carboxy.

In a more preferred embodiment one of \( R_1, R_2 \) and \( R_3 \), represents hydrogen; and the two others of \( R_1, R_2 \) and \( R_3 \) represent methyl, methoxy, halo, trifluoromethyl, cyano or carboxy.

In an even more preferred embodiment one of \( R_1, R_2 \) and \( R_3 \), represents hydrogen or hydroxy; and the two others of \( R_1, R_2 \) and \( R_3 \) represent halo, and in particular fluoro.

In a still more preferred embodiment one of \( R_1, R_2 \) and \( R_3 \), represents hydrogen or hydroxy; and the two others of \( R_1, R_2 \) and \( R_3 \) represent halo, and in particular fluoro.

In a yet more preferred embodiment one of \( R_1, R_2 \) and \( R_3 \), represents hydrogen; and the two others of \( R_1, R_2 \) and \( R_3 \) represent halo, and in particular fluoro.

In a sixth preferred embodiment the aryl piperazine derivative of the invention is a compound of Formula 1, wherein two of \( R_1, R_2 \) and \( R_3 \), represents hydrogen; and the last one of \( R_1, R_2 \) and \( R_3 \) represent methyl, hydroxy, methoxy, halo, trifluoromethyl, cyano or carboxy.

In a more preferred embodiment two of \( R_1, R_2 \) and \( R_3 \), represents hydrogen; and the last one of \( R_1, R_2 \) and \( R_3 \) represent methyl, methoxy, halo, trifluoromethyl, cyano or carboxy.

In an even more preferred embodiment two of \( R_1, R_2 \) and \( R_3 \), represents hydrogen; and the last one of \( R_1, R_2 \) and \( R_3 \) represent hydroxy.

In a most preferred embodiment the aryl piperazine derivative of the invention is

\[ N\text{-}(4\text{-}(4\text{-Phenylpiperazin-1-yl})\text{butyl})\text{quinoline-6-carboxamide}; \text{ or} \]

Quinoline-6-carboxylic acid \{4-[4\text{-}(2,3\text{-difluoro-phenyl})\text{-piperazin-1-yl}]\text{-butyl}\}-amide;

an enantiomer thereof or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
Any combination of two or more of the embodiments described herein is considered within the scope of the present invention.

**Pharmaceutically Acceptable Salts**

The aryl piperazine derivatives of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the aryl piperazine derivatives of the invention.

Examples of pharmaceutically acceptable salts include, without limitation, the non-toxic inorganic and organic acid salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate derived, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by procedures well known and described in the art.

**Steric Isomers**

Some of the aryl piperazine derivatives of the present invention may exist in (+) and (-) forms as well as in racemic forms (±). The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.

Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. A stereo-selective synthetic approach may be pursued. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of D- or L- (tartrates, mandelates, or camphorsulphonate) salts for example.

Starting materials and/or intermediate compounds used for producing the chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the aryl piperazine derivative of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphic acid or by the formation of diastereomeric carbamates by reaction of the starting material or intermediate compound for use according to the present invention with an optically active chloroformate or the like.

Optical active compounds can also be prepared from optical active starting materials.

**Methods of Preparation**

The aryl piperazine derivatives of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.

Generally amides may be prepared by transforming acids or acid chlorides into the corresponding hydroxy amides by a standard procedure. Esters may be obtained by reacting acidic starting materials with 1,4-dihydroxybutane. After substitution of the terminal hydroxy group by bromine, hydroxyl amides may be treated with the aryl piperazine in the presence of a base to give the desired end product. Compounds based on a ethereal tether may be synthesized starting from the appropriate phenol, which is then condensed with 14-dihydroxybutane or 1,5-dihydroxypentane, followed by transformation into the final products as described above.

Intermediate compounds invention may be resolved by the formation of diastereomeric amides by reaction with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the intermediate compound with an optically active chloroformate or the like.

**Biological Activity**

The aryl piperazine derivatives of the invention were found to possess selectivity for the dopamine and serotonin receptors. Therefore, in a preferred embodiment, the invention relates to use of the aryl piperazine derivatives of the invention for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the dopamine and serotonin receptors, in particular the D₃, 5HT₁₉ and 5-HT₂ receptor subtypes.

Moreover, the aryl piperazine derivatives of the invention has no significant activity on hERG, and has a good bioavailability when administered p.o.

Therefore, in a preferred embodiment, the invention relates to use of the aryl piperazine derivatives of the invention for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease,
disorder or condition is responsive to modulation of the dopamine and serotonin receptors.

In a more preferred embodiment the disease, disorder or condition is a neurological or psychiatric disorders, in particular psychotic disorders, incl. schizophrenia, depression, Parkinson's disease, Huntington's disease, movement disorders, in particular dystonia, anxiety, restlessness, obsessive-compulsive disorders, mania, geriatric disorders, dementia, sexual dysfunction, musculo-skeletal pain symptoms, in particular pain associated with fibromyalgia, sleep disorders, substance abuse or addiction, and abuse liability and withdrawal symptoms in drug addicts, cocaine abuse or addiction.

In an even more preferred embodiment the disease, disorder or condition is a neurological or psychiatric disorder, in particular a psychotic disorder, preferably schizophrenia.

In another preferred embodiment the disease, disorder or condition contemplated according to the invention is schizophrenia or Parkinson's disease.

In a third preferred embodiment the disease, disorder or condition contemplated according to the invention an eating disorder, overeating, compulsive overeating, inability to regulate eating, bulimia or Binge-eating disorder.

In a fourth preferred embodiment the disease, disorder or condition contemplated according to the invention is abuse liability or withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, cannabis, benzodiazepines, benzodiazepine-like drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.

In yet another preferred embodiment the aryl piperazine derivatives of the invention are used as diagnostic tools in diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging).

**Pharmaceutical Compositions**

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the aryl piperazine derivative of the invention.

While an aryl piperazine derivative of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
In a preferred embodiment, the invention provides pharmaceutical compositions comprising the aryl piperazine derivative of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

The pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy. Preferred routes of administration include oral administration, in particular in tablet, in capsule, in drage, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition of the invention can be prepared by any person skilled in the art, by use of standard methods and conventional techniques, appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.

Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.

The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 µg/kg i.v. and 1 µg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 µg/kg to about 10 mg/kg/day i.v., and from about 1 µg/kg to about 100 mg/kg/day p.o.

**Methods of Therapy**

In another aspect the invention provides a method for the diagnosis, treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of the dopamine and serotonin receptors, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of an aryl piperazine derivative of the invention.
In the context of this invention the term "treatment" covers treatment, prevention, prophylaxis or alleviation, and the term "disease" covers illnesses, diseases, disorders and conditions related to the disease in question.

The preferred indications contemplated according to the invention are those stated above.

It is at present contemplated that a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.

EXAMPLES

The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

Example 1
Preparatory Example

The synthetic strategy followed to obtain Compounds 5i and 5₂ is reported in Scheme 1, below.

Commercially available 6-methylquinoline was oxidized to the corresponding quinoline-6-carboxylic acid (2) by using chromium trioxide in acidic medium. The acid 2 was transformed, by means of a coupling reaction with 4-aminobutanol, in the presence of 1-hydroxybenzotriazole (HOBT) and 1,3-dicyclohexylcarbodiimide (DCC), into the hydroxyl amide 3. This latter, after bromination of the hydroxyl group, gave the bromo-derivative 4 that was treated with the opportune arylpiperazine in the presence of a base to give the desired products (5i, 2).
Scheme 1.

2,3-Difluoro phenylpiperazine, necessary for the synthesis of 52, was obtained, according to Scheme 2, from Boc-piperazine and 1-bromo-2,3,5 difluorobenzene (6) by a standard palladium catalyzed reaction followed by deprotection with trifluoroacetic acid (TFA).

Scheme 2.

Experimental Section

Reagents were purchased from Aldrich and were used as received. Reaction progress was monitored by TLC using Merk silica gel 60 F254 (0.040-0.063 mm) with detection by UV. Merk silica gel 60 F254 (0.040-0.063 mm) was used for column chromatography.

Melting points were determined in Pyrex capillary tubes using an Electrothermal 8103 apparatus and are uncorrected. 1H NMR and 13C NMR were
recorded on Varian 300 MHz spectrometer with TMS as internal standard. Splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), double doublet (dd) and broad (br); the value of chemical shifts (δ) are given in ppm and coupling constants (J) in Hertz.

ESI-MS spectra were performed by Agilent 1100 Series LC/MSD spectrometer and by LCQDeca-THERMOFINNIGAN spectrometer.

Elemental analyses were performed on a Perkin Elmer 240C elemental analyser and the results were within ± 0.4% of the theoretical values, unless otherwise noted.

Yields refer to purified products and are not optimised. All moisture-sensitive reactions were performed under argon atmosphere using oven-dried glassware and anhydrous solvents. All the organic layers were dried using anhydrous sodium sulphate.

For testing, compound 5t2 was transformed into the corresponding hydrochloride salt by a standard procedure.

6-Quinolinecarboxylic acid (2) (Intermediate compound)

To a solution of 6-methylquinoline (100.0 mg, 0.70 mmol) in H2O (1.0 ml) and H2SO4 (0.25 ml) chromium trioxide (272.0 mg, 2.72 mmol) was added in portions at 0°C and refluxing for twenty-four hours. The crystalline precipitate of the hydrosulphate which separated upon cooling was removed by filtration, dissolved in 10% sodium hydroxide water solution and, after wash with hexane, was reprecipitated with acetic acid to give 85.0 mg of title compound (70% yield) that was used in the following step without further purification. 1H NMR, 300 MHz, (DMSO-^d_6) δ 7.61 (dd, 1H, J1 = 8.3 Hz, J2 = 4.2 Hz), 8.08 (d, 1H, J = 8.8 Hz), 8.20 (dd, 1H, J1 = 8.8 Hz), 8.56 (d, 1H, J = 8.2 Hz), 8.67 (m, 1H), 9.00 (dd, 1H, J1 = 4.1 Hz, J2 = 1.5 Hz), 13.20 (br s, 1H); 13C NMR, 300 MHz, (DMSO-^d_6) 122.9, 127.9, 129.2, 129.5, 130.0, 131.7, 138.2, 150.0, 153.4, 167.7; ESI-MS m/z 196 [M+Na]^+, 174 [M+H]^+. Anal. (C_{10}H_7NO_2) C, H, N.
\(N\)-(4-Hydroxybutyl)quinoline-6-carboxamide (3) (Intermediate compound)

To a solution of 6-quinolinecarboxylic acid (2) (200.0 mg, 1.16 mmol) in dry dichloromethane (20.0 mL), triethylamine (162.0 µL, 1.16 mmol), 1-hydroxybenzotriazole hydrate (17.10 mg, 0.127 mmol) and \(N\)-(3-dimethylaminopropyl)-\(N\)-ethylcarbodiimide hydrochloride (243.0 mg, 1.27 mmol) were added at 0°C under argon atmosphere; the suspension was warmed to room temperature and stirred for 1 h. Then 4-amino-1-butanol (117.0 µL, 1.27 mmol) was added and the mixture was stirred overnight at room temperature. The resulting suspension was evaporated and the crude product was purified by means of flash chromatography (10% methanol in chloroform) to give 275.0 mg of 3 as white solid (97% yield). Mp (methanol) 121-122°C; \(^1\)H NMR, 300 MHz, (CDCl\(_3\)) \(\delta\) 1.67-1.84 (m, 4H), 2.13 (br s, 1H); 3.48-3.59 (m, 2H), 3.76 (m, 2H), 7.02 (br s, 1H), 7.43 (m, 1H), 8.01-8.12 (m, 2H), 8.20 (d, 1H, \(J = 8.5\) Hz), 8.30 (m, 1H), 8.94 (m, 1H). ESI-MS \textit{m/z} 511 [2M+Na]\(^+\), 267 [M+Na]\(^+\), 245 [M+H]\(^+\).

\(N\)-(4-Bromobutyl)quinoline-6-carboxamide (4) (Intermediate compound)

To a solution of \(N\)-(4-hydroxybutyl)quinoline-6-carboxamide (5) (500.0 mg, 2.05 mmol) in dry acetonitrile (30.0 mL), triphenylphosphine (808.0 mg, 3.08 mmol) and carbon tetrabromide (1021.0 mg, 3.08 mmol) were added under vigorous stirring at room temperature. After 2 h the mixture was quenched with 15% NaOH and extracted with EtOAc (3 x 10 mL). The organic layers were dried and evaporated. The residue was chromatographed (10% methanol in chloroform) to give 480.0 mg of 4 (75% yield) as yellow solid. \(^1\)H NMR, 300 MHz, (CDCl\(_3\)) \(\delta\) 1.66 (m, 2H), 1.77 (m, 2H), 3.26 (m, 2H), 3.36 (m, 2H), 7.22 (dd, 1H, \(J_1 = 8.2\) Hz, \(J_2 = 4.4\) Hz), 7.79 (br s, 1H), 7.88 (m, 2H), 7.97 (dd, 1H, \(J_1 = 8.9\) Hz, \(J_2 = 1.9\) Hz), 8.17 (d, 1H, \(J = 1.5\) Hz), 8.75 (dd, 1H, \(J_1 = 4.3\) Hz, \(J_2 = 1.6\) Hz); ESI-MS \textit{m/z} 637 [2M+Na]\(^+\), 330 [M+Na]\(^+\), 308 [M+H]\(^+\). Anal. (C\(_{14}\)H\(_{15}\)Br\(_2\)N\(_2\)O) C, H, N.
In a sealed tube, 1-bromo-2,3-difluorobenzene (517 mg, 2.68 mmol) 
Pd$_2$(dba)$_2$ (2%), BINAP (4%), and sodium t-butoxide (386.4 mg, 4.02 mmol) were 
added to tV-Boc-piperazine (500 mg, 2.68 mmol) and the solids were dissolved in dry 
toluene (5 ml). The mixture was stirred at 70°C for 90 min., filtered over Celite®, 
washing with ethylacetate and the organic layer was evaporated under reduced 
pressure. The crude was purified by flash chromatography (40% ethylacetate in hexane) 
to give 7 as pail yellow solid (95% yield): $^1$H NMR, 300MHz, (CDCl$_3$) $\delta$ 1.38 (s, 9H), 
2.91 (m, 4H), 3.48 (m, 4H), 6.55 (m, 1H), 6.66 (m, 1H), 6.83 (m, 1H). ESI-MS m/z 321 
[M+Na$^+$], 221, 199. Anal (C$_{15}$H$_{20}$F$_2$N$_2$O$_2$) C, H, N.

1-(2,3-Difluorophenyl)piperazine trifluoroacetate (8) (Intermediate compound)

Trifluoroacetic acid (4 ml) was added to 7, cooling in ice bath, and the 
mixture was stirred for 60 min. at room temperature. The crude was concentrated and 
was washed with diethylether till the solid became colorless.

$\mathcal{N}$-(4-(4-Phenylpiperazin-1-yl)butyl)quinoline-6-carboxamide (Compound 5i)

To a stirred solution of $\mathcal{N}$-(4-bromobutyl)quinoline-6-carboxamide (4) (480.0 
mg, 1.56 mmol) in dry acetonithle (30.0 ml) under argon, 1-phenylpiperazine (238.0 
µl, 1.56 mmol) and triethylamine (240.0 µl, 1.72 mmol) were added and the solution 
was refluxed overnight under stirring. The solvent was removed and the crude product 
was chromatographed (10% methanol in chloroform) to give 390.0 mg of 5i (65% 
yield) as white solid: mp (methanol) 151-152°C; $^1$H NMR, 300 MHz, (CDCl$_3$) $\delta$ 1.65- 
1.75 (m, 4H), 2.45 (m, 2H), 2.58 (m, 4H), 3.14 (m, 4H), 3.54 (m, 2H), 6.84 (m, 3H), 
7.07 (br s, 1H), 7.23 (m, 2H), 7.41 (m, 1H), 8.03 (m, 1H), 8.13 (m, 2H), 8.26 (m, 1H),
8.95 (m, 1H); 13C NMR (CDCl3): 24.7, 27.6, 40.4, 49.2, 53.4, 58.1, 116.2, 120.0, 122.1, 127.5, 127.8, 129.3, 130.1, 133.1, 137.1, 149.5, 151.4 (2C\(\delta\)), 125.1, 167.3; ESI-MS m/z 411 [M+Na]+, 389 [M+H]+. Anal. (C24H28N4O) C, H, N.

5 \(\text{N-(4-(2,3-Difluorophenyl)-1-yl)butyl} quinoline-6-carboxamide (Compound 5)\)

To a stirred solution of \(N\text{-}(4\text{-bromobutyl})\text{quinoline-6-carboxamide (4)}\) (120.0 mg, 0.39 mmol) in dry acetonitrile (10.0 mL) under argon, 1-(2,3-difluorophenyl)piperazine trifluoroacetate (8) (181 mg, 0.585 mmol) and triethylamine (109 μL, 0.78 mmol) were added and the solution was refluxed overnight under stirring. The solvent was removed and the crude product was chromatographed (10% methanol in chloroform) to give 100.0 mg of \(5_2\) (60% yield) as amorphous solid: \(^1\text{H} NMR, 300 MHz, (CDCl}_3) \delta 1.72 (m, 4H), 2.47 (t, 2H, \(J = 6.9 \text{ Hz}\)), 2.61 (m, 4H), 3.06 (m, 4H), 3.54 (q, 2H, \(J = 6.1 \text{ Hz}\)), 6.55 (t, 1H, \(J = 7.8 \text{ Hz}\)), 6.76 (m, 1H), 6.92 (m, 2H), 7.45 (m, 1H), 8.03 (m, 1H), 8.15 (m, 1H), 8.25 (m, 1H), 8.29 (m, 1H), 8.97 (m, 1H). ESI-MS m/z 447 [M+Na]+, 425 [M+H]+. Anal. (C_{24}H_{26}F_2N_4O) C, H, N.

Example 2

Biological Activity

20 \(\text{In vitro Binding Studies}\)

The affinity of Compound 5 of the invention for the dopamine and serotonin receptor subtypes was determined using standard receptor binding assays accomplished by MDS Pharma Services using the assay conditions specified below.

From these determinations the Compound 5 of the invention was found to be selective for dopamine D3 and having a Ki in the subnanomolar range.

**Dopamin D3 (MDS Catalog No. 219800)**

- Human recombinant CHO cells
- Ligand = 0.7 nM \([\text{H}]\text{-Spiperone}\)
- Non-specific = 25 μM S(-)-Sulpihde

**Serotonin (5-Hydroxytryptamine) 5-HT1A (MDS Catalog No. 271110)**

- Human recombinant (CHO cells)
- Ligand = 1.5 nM \([\text{H}]\text{-8-OH-DPAT}\)
- Non-specific = 10 μM Metergoline
Serotonin (5-Hydroxytryptamine) 5-HT$_{2A}$ (MDS Catalog No. 271650)

- Human recombinant (CHO cells)
- Ligand = 0.5 nM [³H] Ketanserin
- Non-specific = 1 μM Mianserin
CLAIMS:

1. A n aryl piperazine derivative represented by Formula I

![Chemical Structure](image)

A n enantiomer thereof or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein \(R^1\), \(R^2\) and \(R^3\), independently of each other, represent hydrogen, methyl, hydroxy, methoxy, halo, thfluoromethyl, cyano or carboxy.

2. The aryl piperazine derivative of claim 1, or a pharmaceutically acceptable salt thereof, wherein \(R^1\) and \(R^3\), independently of each other, represent hydrogen, methyl, hydroxy, methoxy, halo or trifluoromethyl.

3. The aryl piperazine derivative of claims 1, or a pharmaceutically acceptable salt thereof, wherein \(R^1\) and \(R^2\), independently of each other, represent hydrogen, halo, hydroxy or trifluoromethyl.

4. The aryl piperazine derivative of claim 1, or a pharmaceutically acceptable salt thereof, wherein \(R^1\) represents hydrogen; and the last one of \(R^1\), \(R^2\) and \(R^3\) represent methyl, hydroxy, methoxy, halo, trifluoromethyl, cyano or carboxy.

5. The aryl piperazine derivative of claim 1, or a pharmaceutically acceptable salt thereof, wherein one of \(R^1\), \(R^2\) and \(R^3\), represents hydrogen or hydroxy; and the two others of \(R^1\), \(R^2\) and \(R^3\), independently of each other, represent methyl, methoxy, halo, trifluoromethyl, cyano or carboxy.

6. The aryl piperazine derivative of claim 1, or a pharmaceutically acceptable salt thereof, wherein two of \(R^1\), \(R^2\) and \(R^3\), represents hydrogen; and the last one of \(R^1\), \(R^2\) and \(R^3\) represent methyl, hydroxy, methoxy, halo, trifluoromethyl, cyano or carboxy.
7. The aryl piperazine derivative of claim 1, which is 
\( \Lambda^-\{(4-(4-\text{Phenylpiperazin}-1-\text{-yl})\text{butyl})\text{quinoline-6-carboxamide; or} \)
Quinoline-6-carboxylic acid \{4-[4-(2,3-difluoro-phenyl)-piperazin-1-yl]-butyl\}-amide;
an enantiomer thereof or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a therapeutically effective amount of an aryl piperazine derivative of any one of claims 1-7, or a pharmaceutically acceptable addition salt thereof, or a prodrug thereof, together with at least one pharmaceutically acceptable carrier or diluent.

9. The aryl piperazine derivative of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, for use as a medicament.

10. Use of the aryl piperazine derivative of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, for the manufacture of a pharmaceutical composition.

11. Use of the aryl piperazine derivative of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the dopamine and serotonin receptors.

12. The use according to claim 11, wherein the disease or a disorder or a condition is a neurological or psychiatric disorders, in particular psychotic disorders, schizophrenia, depression, Parkinson's disease, Huntington's disease, movement disorders, dystonia, anxiety, restlessness, obsessive-compulsive disorders, mania, geriatric disorders, dementia, sexual dysfunction, musculo-skeletal pain symptoms, pain associated with fibromyalgia, sleep disorders, substance abuse or addiction, and abuse liability and withdrawal symptoms in drug addicts, cocaine abuse or addiction.

13. The use according to claim 12, wherein the disease or a disorder or a condition is a neurological or psychiatric disorder, in particular a psychotic disorder, preferably schizophrenia.
14. A method of diagnosis, treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the dopamine and serotonin receptors, in particular the D₃, D₂-like and 5-HT₂ receptor subtypes, preferably the dopamine D₃ receptor subtype and/or the D₃/5-HT₁A or D₃/5-HT₂A receptor subtypes, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of an aryl piperazine derivative according to any one of claims 1-7, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
**A. CLASSIFICATION OF SUBJECT MATTER**

INV. C07D215/48 A61K31/4709 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC.

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

Electronic data base consulted during the international search (name of data base and where practical search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication where appropriate of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2006/072608 A (UNIV SIENA [IT]; CAMPANI GUISEPPE [IT]; BUTINI STEFANIA [IT]; FATTORU) 13 July 2006 (2006-07-13) cited in the application the whole document in particular: compounds 1-29, 1-30, 1-41</td>
<td>1-14</td>
</tr>
<tr>
<td>X</td>
<td>WO 03/028728 A (RICHTER GEDEON VEGYESZET [HU]; NOGRADI KATALIN [HU]; GALAMBUS JANOS [H]) 10 April 2003 (2003-04-10) the whole document in particular: example 9, compounds 70001610, 70001480 example 10, compounds 14103, 14214</td>
<td>1-14</td>
</tr>
</tbody>
</table>

Further special categories of cited documents

- A: document defining the general state of the art which is not considered to be of particular relevance
- E: earlier document but published on or after the international filing date
- L: document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- O: document referring to an oral disclosure, use of exhibition or other means
- P: document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search: 18 January 2008

Date of mailing of the international search report: 30/01/2008

Authorized officer: Papathoma, Sofia
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>LEOPOLDO MARCELLO ET AL: &quot;Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D-3 receptors&quot; JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 1, January 2006 (2006-01), pages 358-365, XP002465112 ISSN: 0022-2623 the whole document in particular: Chart I compound BP-897 Chart II, compound 2 Table 3, compound 29</td>
<td>1-14</td>
</tr>
</tbody>
</table>
# INTERNATIONAL SEARCH REPORT

**Information on patent family members**

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CA 2593266 A1</td>
<td>13-07-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1836192 A2</td>
<td>26-09-2007</td>
</tr>
<tr>
<td>US 4803203 A</td>
<td>07-02-1989</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>